Private payer perspective matters:Guidance for developing a pharmaceutical budget impact analysis.Part 1 of a 2-part series. IntroductionAlthough Canada is recognised as having a publicly funded
Deadline date for switching Patients currently on an originator drug for which there is a biosimilar version for their medical condition must switch to the
April 21, 2020 – Telus Health Canada may see its first gene therapy by the end of this year. The treatment is for a very
Stay tuned for the introduction of our TOTALHealth™ program! To be launched in 2023.